Características farmacoterapêuticas da epilepsia farmacorresistente em adultos: um estudo transversal

Autores

DOI:

https://doi.org/10.11606/issn.2176-7262.rmrp.2025.224790

Palavras-chave:

Medicamentos antiepilépticos, Epilepsias refratárias, Adesão ao medicamento

Resumo

A epilepsia farmacorresistente afeta 30% dos pacientes. O tratamento requer a avaliação da eficácia do medicamento, dos eventos adversos e da adesão do paciente. Objetivo: O objetivo deste estudo é descrever as características farmacoterapêuticas, demográficas e socioeconômicas de pacientes com epilepsia farmacorresistente atendidos em ambulatório especializado, bem como avaliar o conhecimento e a adesão dos pacientes ao tratamento farmacológico e identificar os eventos adversos (EA) mais frequentes. Tipo de estudo e local: estudo transversal realizado no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (HCFMRP) no Brasil. Métodos: entre 28 de agosto e 13 de novembro de 2019, foram incluídos no estudo 217 pacientes com diagnóstico de epilepsia farmacorresistente e em uso de medicamentos antiepilépticos (DAE). Os dados foram coletados por meio de entrevistas com questionário validado e análise de prontuários. Resultados: A politerapia foi prevalente (92,1%). Os DAE mais utilizados foram clobazam, lamotrigina, carbamazepina e topiramato. A pontuação média dos EA foi de 41,4 pontos (desvio padrão [DP] = 11,4). 66,4% tinham acesso gratuito aos medicamentos. O conhecimento dos pacientes sobre a terapia com DAE teve pontuação média de 93,5 pontos (DP = 16,7). Maior conhecimento foi associado a maior adesão (Odds Ratio [OR] = 2,51 | IC95%: 1,11; 5,65) e menor incidência de EA (OR = 0,47 | IC95%: 0,27; 0,83). As taxas de não adesão foram de 47,5% e foram encontradas variáveis significativamente associadas (P ˂ 0,05) à não adesão. Conclusão: os pacientes possuem bom conhecimento sobre o tratamento farmacológico e as prescrições estão de acordo com as diretrizes nacionais, mas são necessários cuidados integrados e contínuos para otimizar a adesão e os serviços de saúde.

Downloads

Os dados de download ainda não estão disponíveis.

Biografia do Autor

  • Paula Sousa França Mencucini, Paula França

    MSc

  • Marília Silveira de Almeida Campos, Federal University of Rio Grande do Sul, Porto Alegre (RS), Brazil

    MSc

  • Vinícius Detoni Lopes, Universidade de São Paulo, Ribeirão Preto (SP), Brazil

    MSc. PhD Candidate

  • João Paulo Vilela Rodrigues, University of São Paulo, Faculty of Pharmaceutical Sciences of Ribeirão Preto, Ribeirão Preto (SP), Brazil

    MSc. PhD Candidate

  • Fabiana Coelho Inouye, University of São Paulo, Faculty of Pharmaceutical Sciences of Ribeirão Preto, Ribeirão Preto (SP), Brazil

    MSc. PhD Candidate

  • Maria Olívia Barboza Zanetti, University of São Paulo, School of Nursing of Ribeirão Preto, Ribeirão Preto (SP), Brazil

     PhD. Professor

  • Fabiana Rossi Varallo, University of São Paulo, Faculty of Pharmaceutical Sciences of Ribeirão Preto, Ribeirão Preto (SP), Brazil

    PhD. Professor

  • Leonardo Régis Leira Pereira, University of São Paulo, Faculty of Pharmaceutical Sciences of Ribeirão Preto, Ribeirão Preto (SP), Brazil

    PhD. Associate Professor

Referências

1. World Health Organization. Adherence to Long Term Therapies: evidence for action. Geneva: WHO; 2003. Available from: https://apps.who.int/iris/handle/10665/42682. Accessed in 2023 (July 14).

2. World Health Organization. Collaborating Centre for Drug Statistics Methodology. Available from: http://www.whocc.no/atcddd. Accessed in 2023 (July 14).

3. Fattorusso A, Matricardi S, Mencaroni E, et al. The pharmacoresistant epilepsy: an overview on existant and new emerging therapies. Front Neurol. 2021;12:674483. PMID: 34239494; https://doi.org/10.3389/fneur.2021.674483.

4. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77. PMID: 19889013; https://doi.org/10.1111/j.1528-1167.2009.02397.x.

5. Baranowski CJ. The quality of life of older adults with epilepsy: A systematic review. Seizure. 2018;60:190-7. PMID: 30031296; https://doi.org/10.1016/j.seizure.2018.06.002.

6. López Gonzáles FJ, Rodríguez Osorio X, Gil-Nagel Rein A, et al. Drug-resistant epilepsy: definition and treatment alternatives. Neurologia. 2015;30(7):439-46. PMID: 24975343; https://doi.org/10.1016/j.nrl.2014.04.012.

7. Palmini A, Viana E. Estratégias medicamentosas nas epilepsias parciais: papel dos diagnósticos sindrômico e subsindrômico. In: Yacubian EMT, Contreras-Caicedo G, Ríos- Pohl L, editors. Tratamento Medicamentoso das Epilepsias. 1ª ed. São Paulo: Leitura Médica, 2014. p. 241-52.

8. Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia. 1997;38(3):353-62. PMID: 9070599; https://doi.org/10.1111/j.1528-1157.1997.tb01128.x.

9. Raehl CL, Bond CA, Woods T, Patry RA, Sleeper RB. Individualized drug use assessment in the elderly. Pharmacotherapy. 2002;22(10):1239-48. PMID: 12389875; https://doi.org/10.1592/phco.22.15.1239.33473.

10. Salgado T, Marques A, Geraldes L, et al. Cross-cultural adaptation of the Beliefs about Medicines Questionnaire into Portuguese. Sao Paulo Med J. 2013;131(2):88-94. PMID: 23657510; https://doi.org/10.1590/s1516-31802013000100018.

11. Svartad BL, Chewning BA, Sleath BL, Claesson C. The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-124. PMID: 14528539; https://doi.org/10.1016/s0738-3991(98)00107-4.

12. Meiners MMMA, Tavares NUL, Guimarães LSP, et al. Access and adherence to medication among people with diabetes in Brazil: evidences from PNAUM. Rev Bras Epidemiol. 2017;20(3):445-59. PMID: 29160437; https://doi.org/10.1590/1980-5497201700030008.

13. Brasil. Manual do instrumento de avaliação da atenção primária à saúde: primary care assessment tool PCATool-Brasil. Brasília-DF: Ministério da Saúde; 2010. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/manual_avaliacao_pcatool_brasil.pdf. Accessed in 2023 (Jul. 18).

14. Bourgeois BF. Reducing overtreatment. Epilepsy Res. 2002;52(1):53-60. PMID: 12445960; https://doi.org/10.1016/s0920-1211(02)00185-7.

15. Medronho, RA. Epidemiologia. São Paulo: Atheneu; 2003.

16. Banco Central do Brasil. Currency Conversion on November 11, 2019. Available from: https://www.bcb.gov.br/en/currencyconversion. Accessed in 2023 (Jul. 18).

17. Noronha AL, Borges MA, Marques LH, et al. Prevalence and pattern of epilepsy treatment in different socioeconomic classes in Brazil. Epilepsia. 2007;48(5):880-5. PMID: 17326788; https://doi.org/10.1111/j.1528-1167.2006.00974.x.

18. Fernandes P, Meiga C, Peres AC, et al. Translation of social and occupational functioning scale for epilepsy into Portuguese - Brazil. Arq Neuropsiquiatr. 2017;75(9):639-48. PMID: 28977145; https://doi.org/10.1590/0004-282x20170099.

19. Gomes DC, Costa-Paiva L, Farhat FC, Pedro AO, Pinto-Neto AM. Ability to follow anti-reabsorptive drug treatment in postmenopausal women with reduced bone mass. Menopause. 2011;18(5):531-6. PMID: 21242816; https://doi.org/10.1097/gme.0b013e3181fda7e7.

20. Malerba A, Ciampa C, De Fazio S, et al. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res. 2010;91(2-3):273-82. PMID: 20810249; https://doi.org/10.1016/j.eplepsyres.2010.08.002.

21. Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia. 2010;51(5):797-804. PMID: 20545754; https://doi.org/10.1111/j.1528-1167.2010.02520.x.

22. Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy pursuing seizure freedom and tolerability in adults. Curr Opin Neurol. 2012;25(2):164-72. PMID: 22322411; https://doi.org/10.1097/wco.0b013e328350ba68.

23. Ostendorf AP, Ahrens SM, Lado FA, et al. United States Epilepsy Center Characteristics: a data analysis from the National Association of Epilepsy Centers. Neurology. 2022;98(5):e449-58. PMID: 34880093; https://doi.org/10.1212/wnl.0000000000013130.

24. Arrais PS, Fernandes ME, Pizzol TD, et al. Prevalence of self-medication in Brazil and associated factors. Rev Saúde Pública. 2016;50(suppl 2):13s. PMID: 27982373; https://doi.org/10.1590/s1518-8787.2016050006117.

25. Sirven JI, Noe K, Hoerth M, Drazkowski J. Antiepileptic drugs 2012: recent advances and trends. Mayo Clin Proc. 2012;87(9):879-89. PMID: 22958992; https://doi.org/10.1016/j.mayocp.2012.05.019.

26. da Silveira MRM, Montenegro MA, Franzon RC, Guerreiro CAM, Guerreiro MM. Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy. Arq Neuropsiquiatr. 2006;64(3B):705-10. PMID: 17057871; https://doi.org/10.1590/s0004-282x2006000500001.

27. Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95(1-2):51-9. PMID: 21435840; https://doi.org/10.1016/j.eplepsyres.2011.02.012.

28. Alacqua M, Trifirò G, Spina E, et al. Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003-2005. Epilepsy Res. 2009;85(1):107-13. PMID: 19345564; https://doi.org/10.1016/j.eplepsyres.2009.03.002.

29. Mercadé Cerdá JM, Toledo Argani M, Mauri Llerda JA, et al. The Spanish Neurological Society official clinical practice guidelines in epilepsy. Neurologia. 2016;31(2):121-9. PMID: 24636132; https://doi.org/10.1016/j.nrl.2013.12.020.

30. Brasil. Ministério da Saúde. Portaria conjunta n. 17, de 21 de junho de 2018. Aprova o Protocolo Clínico e Diretrizes Terapêuticas de Epilepsia. Diário Oficial da União Edição. 2018;122:45. Available from: https://www.gov.br/saude/pt-br/assuntos/protocolos-clinicos-e-diretrizes-terapeuticas-pcdt/arquivos/2021/portal-portaria-no-17-pcdt-epilepsia.pdf. Accessed in 2023 (Jul. 18).

31. Paniz VM, Fassa AG, Maia MF, Domingues MR, Bertoldi AD. Measuring access to medicines: a review of quantitative methods used in household surveys. BMC Health Serv Res. 2010;10:146. PMID: 20509960; https://doi.org/10.1186/1472-6963-10-146.

32. Green SF, Hare N, Kassam M, et al. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center. Epilepsy Behav. 2022;135:108868. PMID: 35985166; https://doi.org/10.1016/j.yebeh.2022.108868.

33. Lossius IMB, Svendsen T, Sødal HF, et al. Effect and tolerability of perampanel in patients with drug-resistant epilepsy. Epilepsy Behav. 2021;119:107965. PMID: 33940525; https://doi.org/10.1016/j.yebeh.2021.107965.

34. Shorvon SD. Handbook of Epilepsy Treatment. Chichester: Wiley Blackwell; 2010.

35. Andrew T, Milinis K, Baker G, Wieshmann U. Self-reported adverse effects of mono and polytherapy for epilepsy. Seizure. 2012;21(8):610-3. PMID: 22795388; https://doi.org/10.1016/j.seizure.2012.06.013.

36. Gilliam FG, Fessler AJ, Baker G, et al. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62(1):23-7. PMID: 14718691; https://doi.org/10.1212/wnl.62.1.23.

37. Thijs RD, Surges R, O'Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689-701. PMID: 30686584; https://doi.org/10.1016/s0140-6736(18)32596-0.

38. Betting LE, Guerreiro CAM. Partial epilepsies treatment. J Epilepsy Clin Neurophysiol. 2008;14(suppl 2):25-31. https://doi.org/10.1590/S1676-26492008000600005.

39. Siqueira HH, Dalbem JS, Schiavini M, et al. Self-reported adherence among people with epilepsy in Brazil. Epilepsy Behav. 2020;103:106498. PMID: 31653605; https://doi.org/10.1016/j.yebeh.2019.106498.

40. Ben AJ, Neumann CR, Mengue SS. The Brief Medication Questionnaire and Morisky-Green Test to evaluate medication adherence. Rev Saúde Pública 2012;46(2):279-89. PMID: 22331180; https://doi.org/10.1590/s0034-89102012005000013.

41. Chapman SC, Horne R, Chater A, Hukins D, Smithson WH. Patients' perspectives on antiepileptic medication: relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care. Epilepsy Behav. 2014;31:312-20. PMID: 24290250; https://doi.org/10.1016/j.yebeh.2013.10.016.

42. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555-67. PMID: 10661603; https://doi.org/10.1016/s0022-3999(99)00057-4.

43. Yang C, Hao Z, Yu D, Xu Q, Zhang L. The prevalence rates of medication adherence and factors influencing adherence to antiepileptic drugs in children with epilepsy: a systematic review and meta-analysis. Epilepsy Res. 2018;142:88-99. PMID: 29609075; https://doi.org/10.1016/j.eplepsyres.2018.03.018.

44. Fogg A, Staufenberg EF, Small I, Bhattacharya D. An exploratory study of primary care pharmacist-led epilepsy consultations. Int J Pharm Pract. 2012;20(5):294-302. PMID: 22953768; https://doi.org/10.1111/j.2042-7174.2012.00207.x.

45. Obreli-Neto PR, Marques Dos Reis T, Guidoni CM, et al. A systematic review of the effects of continuing education programs on Providing Clinical Community Pharmacy Services. Am J Pharm Educ. 2016;80(5):88. PMID: 27402991; https://doi.org/10.5688/ajpe80588.

46. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):82-90. PMID: 29898974; https://doi.org/10.1212/wnl.0000000000005756.

47. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults. 2015. Available from: https://www.sign.ac.uk/our-guidelines/diagnosis-and-management-of-epilepsy-in-adults/. Accessed in 2023 (Jul. 18).

48. Boon P, Ferrao Santos S, Jansen AC, et al. Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update. Acta Neurol Belg. 2021;121(1):241-57. PMID: 33048338; https://doi.org/10.1007/s13760-020-01488-y.

Downloads

Publicado

2026-02-13

Edição

v. 58 n. 3 (2025)

Seção

Artigo Original

Licença

Direitos autorais (c) 2026 Paula Sousa França Mencucini, Marília Silveira de Almeida Campos, Vinícius Detoni Lopes, João Paulo Vilela Rodrigues, Fabiana Coelho Inouye, Maria Olívia Barboza Zanetti, Fabiana Rossi Varallo, Leonardo Régis Leira Pereira

Creative Commons License

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

 

 

Como Citar

1.
Sousa França Mencucini P, Campos MS de A, Lopes VD, Rodrigues JPV, Inouye FC, Zanetti MOB, et al. Características farmacoterapêuticas da epilepsia farmacorresistente em adultos: um estudo transversal. Medicina (Ribeirão Preto) [Internet]. 13º de fevereiro de 2026 [citado 14º de fevereiro de 2026];58(3):e-224790. Disponível em: https://revistas.usp.br/rmrp/article/view/224790